Prelude Therapeutics Incorporated
PRLD
PRLD: Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
moreShow PRLD Financials
Recent trades of PRLD by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by PRLD's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Followers on PRLD's company Twitter account
Number of mentions of PRLD in WallStreetBets Daily Discussion
Recent insights relating to PRLD
Recent picks made for PRLD stock on CNBC
ETFs with the largest estimated holdings in PRLD
Flights by private jets registered to PRLD